Cogent Biosciences, Inc. (COGT)
- Previous Close
6.96 - Open
6.95 - Bid 6.52 x 500
- Ask 6.56 x 1200
- Day's Range
6.54 - 7.11 - 52 Week Range
3.67 - 13.50 - Volume
1,512,642 - Avg. Volume
2,166,566 - Market Cap (intraday)
665.471M - Beta (5Y Monthly) -0.08
- PE Ratio (TTM)
-- - EPS (TTM)
-2.42 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
16.70
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
www.cogentbio.comRecent News: COGT
Performance Overview: COGT
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: COGT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: COGT
Valuation Measures
Market Cap
625.31M
Enterprise Value
438.49M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.16
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-2.14
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-42.36%
Return on Equity (ttm)
-74.93%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-192.41M
Diluted EPS (ttm)
-2.42
Balance Sheet and Cash Flow
Total Cash (mrq)
265.71M
Total Debt/Equity (mrq)
7.31%
Levered Free Cash Flow (ttm)
-86.68M